Chiron Capital Management LLC Reduces Stock Holdings in Albemarle Corporation $ALB

Chiron Capital Management LLC cut its stake in shares of Albemarle Corporation (NYSE:ALB) by 21.6% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 12,311 shares of the specialty chemicals company’s stock after selling 3,398 shares during the period. Chiron Capital Management LLC’s holdings in Albemarle were worth $998,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ALB. BOKF NA grew its position in Albemarle by 5,771.4% in the third quarter. BOKF NA now owns 411 shares of the specialty chemicals company’s stock valued at $33,000 after acquiring an additional 404 shares in the last quarter. Cromwell Holdings LLC lifted its position in shares of Albemarle by 36.8% during the third quarter. Cromwell Holdings LLC now owns 413 shares of the specialty chemicals company’s stock worth $34,000 after purchasing an additional 111 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Albemarle by 536.7% in the second quarter. EverSource Wealth Advisors LLC now owns 573 shares of the specialty chemicals company’s stock valued at $36,000 after purchasing an additional 483 shares during the period. Physician Wealth Advisors Inc. purchased a new position in shares of Albemarle in the third quarter valued at $40,000. Finally, Hantz Financial Services Inc. grew its holdings in Albemarle by 70.4% during the 3rd quarter. Hantz Financial Services Inc. now owns 692 shares of the specialty chemicals company’s stock valued at $56,000 after purchasing an additional 286 shares in the last quarter. Hedge funds and other institutional investors own 92.87% of the company’s stock.

Albemarle Price Performance

Shares of ALB stock opened at $158.00 on Friday. The firm has a fifty day moving average of $170.89 and a two-hundred day moving average of $128.66. The firm has a market cap of $18.59 billion, a P/E ratio of -27.48, a P/E/G ratio of 1.21 and a beta of 1.43. Albemarle Corporation has a 1-year low of $49.43 and a 1-year high of $206.00. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.23 and a quick ratio of 1.57.

Albemarle (NYSE:ALB) last issued its earnings results on Wednesday, February 11th. The specialty chemicals company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.13). Albemarle had a negative net margin of 10.74% and a positive return on equity of 0.41%. The company had revenue of $1.43 billion during the quarter, compared to analyst estimates of $1.34 billion. During the same quarter last year, the company posted ($1.09) EPS. The business’s revenue for the quarter was up 15.9% compared to the same quarter last year. As a group, research analysts anticipate that Albemarle Corporation will post -0.04 earnings per share for the current fiscal year.

Albemarle Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Friday, March 13th will be paid a dividend of $0.405 per share. The ex-dividend date is Friday, March 13th. This represents a $1.62 annualized dividend and a yield of 1.0%. Albemarle’s dividend payout ratio is presently -28.17%.

Analysts Set New Price Targets

ALB has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Albemarle in a research note on Monday, December 29th. UBS Group upped their price objective on shares of Albemarle from $185.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Deutsche Bank Aktiengesellschaft lifted their target price on Albemarle from $185.00 to $195.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Morgan Stanley boosted their price target on Albemarle from $147.00 to $170.00 and gave the stock an “equal weight” rating in a research note on Friday, February 13th. Finally, Mizuho increased their price target on Albemarle from $156.00 to $185.00 and gave the company a “neutral” rating in a report on Thursday, February 12th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $170.24.

Insider Transactions at Albemarle

In other Albemarle news, CEO J Kent Masters sold 11,783 shares of the stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $170.81, for a total transaction of $2,012,654.23. Following the transaction, the chief executive officer owned 134,628 shares of the company’s stock, valued at $22,995,808.68. This trade represents a 8.05% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.33% of the stock is owned by insiders.

Key Stories Impacting Albemarle

Here are the key news stories impacting Albemarle this week:

• Positive Sentiment: Company confirmed a quarterly dividend of $0.405 per share (ex-dividend March 13), supporting income-focused demand and signaling confidence in cash flow. Albemarle Declares Quarterly Dividend
• Positive Sentiment: Board refresh and strategic moves: Albemarle added two finance executives to the board, launched up to $500M of debt tender offers, redeemed 2027 notes and announced a planned sale of a controlling interest in its Ketjen business — actions that can improve capital structure and focus the portfolio. Board refresh, Ketjen sale and debt moves
• Positive Sentiment: Several sell-side analysts remain constructive or raised targets (UBS, Jefferies, Argus), leaving an overall “Moderate Buy” consensus and supporting upside potential if lithium demand recovers. MarketBeat analyst summary
• Neutral Sentiment: Zacks pieces note mixed short-term moves (e.g., ALB was up ~3.1% since the last earnings report in one write-up) and provide context rather than new fundamental news — useful for sentiment but not a direct catalyst. Why Is Albemarle Up 3.1% Since Last Earnings?
• Negative Sentiment: CEO J. Kent Masters sold 11,783 shares (~$2.0M) on March 10, reducing his stake ~8% — insider selling often spooks investors and can add near-term downward pressure. Insider sale filing
• Negative Sentiment: Recent quarterly results (Feb. 11) showed an EPS miss (‑$0.53 vs. est. ‑$0.40) despite revenue beating; negative net margin and continued quarterly losses keep near-term profitability under scrutiny. Earnings and financials summary
• Negative Sentiment: Zacks and MarketBeat noted the stock has declined more than the broader market in recent sessions, reflecting the combined effect of the earnings miss, insider selling and broader commodity/EV cycle sentiment. ALB sees dip vs. market

Albemarle Profile

Albemarle Corporation is a leading global specialty chemicals company primarily engaged in the production and distribution of lithium, bromine, and catalysts. Its lithium segment supplies key components used in rechargeable batteries for electric vehicles, portable electronics, and grid storage systems. The company’s bromine specialty products serve a wide range of industries, including oil and gas drilling fluids, fire safety solutions, and water treatment. In its catalysts division, Albemarle provides products for petroleum refining, chemical processing and emissions control.

Founded in 1994 as a spin-off from Ethyl Corporation, Albemarle has grown through strategic acquisitions and capacity expansions to become one of the world’s foremost chemical producers.